Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARCT-154 COVID-19 vaccine in adults
NCT05012943Phase 3Completed
- Sponsor
- VinBioCare Biotechnology Joint Stock Company
- Start
- Aug 2021
- Primary completion
- Jan 2023
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of ARCT-154 in coronavirus disease 2019 (COVID-19), sponsored by VinBioCare Biotechnology Joint Stock Company. Started Aug 2021; status: completed.
02
Drugs
ARCT-154
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05012943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05012943.